Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02974153 · ClinicalTrials.gov registry record · Phase 3
Evaluation of ALD403 (Eptinezumab) in the Prevention of Chronic Migraine
A Phase 3 study, sponsored by Alder Biopharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,121
- Enrollment target
NCT02974153: Completed Phase 3 study, sponsored by Alder Biopharmaceuticals.
NCT02974153 is a Phase 3 study that has completed, run by Alder Biopharmaceuticals. The registered enrollment target is 1,121 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (45% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02974153, a Phase 3 study, has completed, sponsored by Alder Biopharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,121 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the efficacy and safety of ALD403 in the prevention of migraine headache in chronic migraineurs.
Primary Outcome
Monthly migraine days are summarized in 28-day intervals, and averaged across Weeks 1-12
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL ALD403 (Eptinezumab)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,121 participants |
| Start Date | 2016-11 |
| Est. Completion | 2018-04 |
| Phase | Phase 3 |
What the finished NCT02974153 record still lists
NCT02974153 is an interventional study that assigns participants to a tested intervention. Its 1,121 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (45% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02974153 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02974153 about?
NCT02974153 is a clinical study titled "Evaluation of ALD403 (Eptinezumab) in the Prevention of Chronic Migraine". The purpose of this study is to assess the efficacy and safety of ALD403 in the prevention of migraine headache in chronic migraineurs.
What is the current status of trial NCT02974153?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,121 participants. The study started on 2016-11. Estimated completion is 2018-04.
What interventions are being tested in trial NCT02974153?
The interventions under investigation include: Placebo (BIOLOGICAL), ALD403 (Eptinezumab) (BIOLOGICAL).
Who is sponsoring clinical trial NCT02974153?
This trial is sponsored by Alder Biopharmaceuticals, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02974153's enrollment target sits among peer trials
1,121 249th of 2000 higher than 1,752 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05691478 · 1,122 participants · Phase 2
A Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients With Newly Diagnosed Osteosarcoma
- NCT02140255 · 1,120 participants · Phase 1
Very Early Intensive Treatment of Infants Living With HIV to Achieve HIV Remission
- NCT06618534 · 1,120 participants · Phase 2
Azithromycin for Meningococcal Carriage
- NCT07164131 · 1,120 participants · Phase 4
Azithromycin Versus Doxycycline in Hospitalized Adult Patients With Community Acquired Pneumonia Treated With Beta-lactams
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia